Cingulate Inc. (CINGW) Aandelenanalyse

Bedrijfsoverzicht

Cingulate Inc. is a biopharmaceutical entity dedicated to the development of pharmaceutical products utilizing proprietary drug delivery platform technology, specifically targeting the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety within the United States market. The company operates within the biopharmaceutical sector, an industry characterized by high research and development costs and significant regulatory hurdles, where its focus on novel delivery mechanisms for central nervous system disorders distinguishes its operational scope. Regarding its scale, Cingulate Inc. reports a market capitalization and annual revenue that are not available in the current dataset, while the organization employs a total workforce of 14 individuals. The absence of disclosed market cap and revenue figures suggests that the company is in an early-stage development phase typical for pre-revenue or pre-profit biopharmaceutical firms, indicating a position where value is derived primarily from intellectual property potential rather than established commercial cash flows.

Financiële gezondheid

The financial statements for Cingulate Inc. reveal a revenue (TTM) figure that is not available, while the net income (TTM) stands at a negative $22,449,912 and the EBITDA is recorded at $-19,397,214. The substantial gap between the unlisted revenue and the significant net loss indicates that the company's cost structure currently consists of expenses that far exceed any generated income, a common characteristic in the drug discovery and development lifecycle before product approval. Free cash flow is reported at $-10,425,198, which signifies a continuous consumption of cash reserves to fund operations and research activities, thereby limiting immediate financial flexibility without external capital injections. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet generated profitable sales to calculate meaningful margin percentages, reflecting its status as an investment in future potential rather than a current profit generator. On the balance sheet, the company holds $10.95M in cash against $8.79M in debt, resulting in a debt-to-equity ratio of 350.21, which suggests a highly leveraged position relative to equity but implies that the absolute debt burden is manageable given the cash on hand. The current ratio is 1.16, indicating that the company possesses slightly more current assets than current liabilities, which points to a marginally adequate but not robust short-term liquidity position. Return on equity is -450.6% and return on assets is -83.2%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the company, highlighting the high risk associated with the business model at this stage.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio and forward P/E ratio for Cingulate Inc. are both listed as N/A, implying that no earnings-based valuation multiples can be calculated due to the company's lack of profitability, which prevents the use of standard price-to-earnings analysis for assessing expected earnings trajectory. The price-to-book ratio is 0.08, a figure that indicates the company's market capitalization is trading at a fraction of its book value, suggesting that the market assigns a low premium to the company's tangible assets or that intangible assets like intellectual property are not fully captured in the book value. The price-to-sales ratio and EV/EBITDA are also not available (N/A), meaning alternative valuation metrics typically used for mature companies cannot be applied, as the denominator for these ratios is either zero or negative. The 52-week high and low are both recorded at $0.03, meaning the current trading price is effectively trading at 0% below the 52-week high and 0% above the 52-week low, indicating a stock with no price movement over the last year. The beta value is -0.77, which is a negative figure that suggests the stock price moves inversely to the broader market, exhibiting a volatility profile that is statistically distinct from the positive correlation usually observed in equity markets.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is insufficient historical data to calculate growth rates, likely due to the company being in its early operational stages or having minimal recent commercial activity. Since the company does not pay a dividend, there is no dividend yield or payout ratio to analyze, meaning the payout ratio is not applicable and the company does not distribute earnings to shareholders. Instead of paying dividends, Cingulate Inc. must reinvest its limited financial resources, specifically the $10.95M in cash, into research and development to pursue its lead product candidate CTx-1301. The overall growth and income profile is currently defined by a lack of historical growth data and a complete absence of dividend income, positioning the asset as a pure play on future pharmaceutical breakthroughs rather than a vehicle for current income generation or established growth metrics.